American Leprosy Missions meets the 20 Standards for Charity Accountability.
American Leprosy Missions (ALM) covers costs of treating leprosy in countries in Africa and Asia that have the highest detection rates for the disease. The organization also funds reconstructive, cosmetic, and other surgical procedures to alleviate the damage from leprosy to the body, provides physical therapy rehabilitation programs, and offers patients help in starting businesses and learning job skills such as carpentry or sewing. In addition to research grants aimed at improving the screening and assessment of patients, ALM funds the development of a leprosy vaccine. At ALM-supported hospitals, health workers receive training in recognizing and treating leprosy. The organization also sponsors broadcasts and produces materials including books, brochures and posters for health clinics designed to teach recognition of early warning signs as well as reduce the fear and stigma associated with leprosy. ALM is also carrying out a campaign against Buruli ulcer (a flesh-destroying bacterium closely related to leprosy) in Cote d"Ivoire, Ghana, Liberia and the Democratic Republic of the Congo.
For the year ended June 30, 2018, American Leprosy Missions's program expenses were:
Program services |
$11,770,082 |
Total Program Expenses: |
$11,770,082 |
-
Chief Executive
David W. Simmons, President and Chief Executive Officer
-
Compensation*
$191,056
-
Chair of the Board
Neal Joseph
-
Chair's Profession / Business Affiliation
Vice President for Nonprofit Search and Consulting, Slingshot Group
-
Board Size
11
-
Paid Staff Size
18
July 1, 2016 - June 30, 2017 compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.
Method(s) Used:
Direct mail appeals, Grant proposals, Internet, Invitations to fund raising events, Planned giving arrangements, Print advertisements (newspapers, magazines, etc.), Telephone appeals, Radio
Fundraising costs were 12% of related contributions. (Related contributions, which totaled $19,511,073, are donations received as a result of fundraising activities.)
This organization is tax-exempt under section 501(c) (3) of the Internal Revenue Code.It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on American Leprosy Missions's audited financial statements for the year ended June 30, 2018.
Source of Funds |
Contributions |
$10,779,777 |
In-kind contributions |
$6,333,138 |
Legacies and bequests |
$1,492,692 |
Special events |
$436,174 |
Income from outside trusts |
$235,288 |
Investment income, net |
$126,348 |
Realized gain on investment transactions |
$79,579 |
Unrealized gain on investments, net |
$46,905 |
Investment return in excess of amount designated for current operations |
$17,945 |
Other |
$1,180 |
Total Income |
$19,549,026 |
- Programs: 81%
- Fundraising: 16%
- Administrative: 3%
Total Income |
$19,549,026 |
Program expenses |
$11,770,082 |
Fundraising expenses |
$2,345,410 |
Administrative expenses |
$499,083 |
Other expenses |
$0 |
Total expenses: |
$14,614,575 |
Income in Excess of Expenses |
$4,934,451 |
Beginning Net Assets |
$10,662,497 |
Other Changes In Net Assets |
$342,736 |
Ending Net Assets |
$15,939,684 |
Total Liabilities |
$305,635 |
Total Assets |
$16,245,319 |
Note 1: According to the audited financial statements for the year ended June 30, 2018, ALM recieved in-kind medical supply donations valued at $6,333,138.
Note 2: In the above financial section, "other changes in net assets" represent a change in beneficial interest in perpetual trusts ($355,604) and actuarial loss on annuity and unitrust obligations (-$12,868).